Xylem's Short Sellers Keep Retreating After the Earnings Shock

Xylem is a week into its recovery from the October 27 earnings collapse, and the most striking development is not what the stock has done but what short sellers have done: they have continued to exit at an accelerating pace.

Short interest has dropped 23% over the past week to 3.3% of the free float, now at roughly 8 million shares. That is a move 2.3 standard deviations below the typical weekly change for XYL over the past year. Since peaking above 11.3 million shares in mid-October, shorts have unwound more than a quarter of their position. The borrow market reinforces the picture of an orderly retreat rather than a forced one. Availability has surged to 1,077%, up 63% on the week, meaning there are more than ten shares available to lend for every one already borrowed. Cost to borrow has dropped alongside, falling 21% to 0.35%, its lowest reading in the 30-day window. Nothing in the lending market suggests shorts are being squeezed out; they are leaving on their terms.

Options positioning has turned more bullish relative to recent history. The put/call ratio fell to 0.67, now more than 1.2 standard deviations below its 20-day mean of 0.82. As recently as October 29, the ratio spiked to 1.08 as the selloff landed, but that defensive burst has fully unwound. The 52-week range on the PCR runs from 0.16 to 1.15, so the current reading sits in the lower half, tilted toward calls. Combined with the short exit data, the overall positioning picture looks more like stabilisation than an ongoing bear case.

The Street is split on what stabilisation is worth. Most firms who cover the stock cut targets after the earnings miss but kept positive ratings. Goldman Sachs holds Buy with a $138 target. Citigroup holds Buy at $130. BNP Paribas and Oppenheimer both rate Outperform with targets of $135. RBC Capital sits at $125 Outperform, Stifel at $114 Buy. The consensus mean now stands at $125.44, against a close of $96.27. That 30% gap is wide. It reflects the tension between a bullish structural view on water infrastructure and a near-term demand profile that the company itself called flat for organic growth. The bear case is concrete: three of four segments missed 3Q26 revenue expectations, the full-year EPS guide was cut to $5.40 to $5.45, and Q4 organic growth is guided to minus 2% to minus 1%. The bull case rests on orders that rose 10% and backlog that climbed to $5.5 billion, plus a planned restructuring into three cleaner segments from January 1, 2027. Argus Research added a downgrade to Hold on November 4, moving in the same direction as Barclays and JP Morgan from last week, though the majority of the desk remains constructive.

The director purchase that stood out in earlier notes remains the only open-market buying in the past 90 days. D. Christian Koch bought 11,000 shares at $89.60 on October 29, committing just under $1 million without a 10b5-1 plan. The stock has since recovered to $96.27, up 7% from his entry. The 90-day net insider position is 11,000 shares at a net value of $985,600. All other recent insider transactions were grants and tax-withholding events, which carry no directional read. BlackRock holds 10.9% of shares and State Street added 271,000 shares to its position as of September 30, though institutional data lags by a quarter and the picture there predates the earnings event.

Retail attention, separately, has spiked sharply. Wikipedia page views and ORTEX stock page traffic have combined to a z-score of 3.4 against Xylem's own 90-day history, one of the stronger attention readings in the dataset. This is a measure of interest, not a revenue or earnings indicator, but it reflects how much the October 27 event drew eyes to a stock that had largely traded out of the headlines.

The next earnings date is February 3, 2027, leaving 91 days for the market to reconcile a 30% gap between price and consensus target, a backlog that management describes as healthy, and guidance that implies Q4 will be worse before it gets better.